CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:EEG-based grading of immune effector cell-associated neurotoxicity syndrome.
EEG-based grading of immune effector cell-associated neurotoxicity syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法是治疗多种难治/复发性血液系统恶性肿瘤的有效癌症疗法,但与显著毒性相关,包括免疫效应细胞相关神经毒性综合征(ICANS)。改进ICANS的检测和评估可以改善管理并允许更充分地利用CAR-T 细胞疗法,然而,尚未确定客观、特异的生物标志物。
我们假设ICANS的严重程度可以基于脑电图(EEG)信号中观察到的异常脑活动模式进行量化。我们对120例接受过EEG监测的CAR-T 细胞疗法患者进行了回顾性观察性研究。
我们通过病历审查确定每位患者的每日ICANS分级。我们使用视觉评估的EEG特征和机器学习技术开发了视觉EEG-免疫效应细胞相关神经毒性综合征(VE-ICANS)评分,并评估了VE-ICANS与ICANS之间的关联。
我们还使用它来确定EEG特征的意义和相对重要性。我们开发了视觉EEG-ICANS(VE-ICANS)分级量表,这是一个具有生理基础的分级量表,与ICANS严重程度有强相关性(R = 0.58 [0.47-0.66]),并通过受试者工作特征曲线下面积测量具有极好的区分度(ICANS 2的AUC = 0.91)。该量表显示出作为ICANS生物标志物的前景,可能通过更准确地评估ICANS严重程度来帮助改善临床护理。
CAR-T cell therapy is an effective cancer therapy for multiple refractory/relapsed hematologic malignancies but is associated with substantial toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS). Improved detection and assessment of ICANS could improve management and allow greater utilization of CAR-T cell therapy, however, an objective, specific biomarker has not been identified.
We hypothesized that the severity of ICANS can be quantified based on patterns of abnormal brain activity seen in electroencephalography (EEG) signals.
We conducted a retrospective observational study of 120 CAR-T cell therapy patients who had received EEG monitoring.
We determined a daily ICANS grade for each patient through chart review.
We used visually assessed EEG features and machine learning techniques to develop the Visual EEG-Immune Effector Cell Associated Neurotoxicity Syndrome (VE-ICANS) score and assessed the association between VE-ICANS and ICANS.
We also used it to determine the significance and relative importance of the EEG features.
We developed the Visual EEG-ICANS (VE-ICANS) grading scale, a grading scale with a physiological basis that has a strong correlation to ICANS severity (R = 0. 58 [0. 47-0. 66]) and excellent discrimination measured via area under the receiver operator curve (AUC = 0. 91 for ICANS 2). This scale shows promise as a biomarker for ICANS which could help to improve clinical care through greater accuracy in assessing ICANS severity.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。